CompanyPBM PBMWWNasdaqToronto

Psyence Biomedical Ltd.

Psyence Biomedical develops psilocybin and ibogaine-based neuroplastogen therapeutics for mental health disorders.

SEC EDGAR ClinicalTrials.gov psylabs.life

6-KOct 21Latest SEC filing

Oct 5Latest story

October 2026

Psyence BioMed's Texas unit signs manufacturing pact with Benuvia for ibogaine API

Oct 5PartnershipPsyence Biomedical Ltd.